miR-92a-3p regulates cisplatin-induced cancer cell death

[1]  Sanjeev Gupta,et al.  The miR-17-92 cluster: Yin and Yang in human cancers. , 2022, Cancer treatment and research communications.

[2]  Jennifer B Dennison,et al.  Contributions of Circulating microRNAs for Early Detection of Lung Cancer , 2022, Cancers.

[3]  Z. Ye,et al.  Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer , 2022, Applied bionics and biomechanics.

[4]  C. Féral,et al.  Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine , 2022, Cancers.

[5]  Jing Hai,et al.  MicroRNA-92a-3p Enhances Cisplatin Resistance by Regulating Krüppel-Like Factor 4-Mediated Cell Apoptosis and Epithelial-to-Mesenchymal Transition in Cervical Cancer , 2022, Frontiers in Pharmacology.

[6]  Yijun Wang,et al.  miR‐92a promotes cervical cancer cell proliferation, invasion, and migration by directly targeting PIK3R1 , 2021, Journal of clinical laboratory analysis.

[7]  O. Chabre,et al.  MicroRNA Therapeutics in Cancer: Current Advances and Challenges , 2021, Cancers.

[8]  Yun Fan,et al.  KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup , 2021, Frontiers in Oncology.

[9]  Huang Jinghua,et al.  MicroRNA miR-92a-3p regulates breast cancer cell proliferation and metastasis via regulating B-cell translocation gene 2 (BTG2) , 2021, Bioengineered.

[10]  E. Imyanitov,et al.  Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. , 2020, Critical reviews in oncology/hematology.

[11]  M. Tsao,et al.  Circulating miR-16-5p, miR-92a-3p, and miR-451a in Plasma from Lung Cancer Patients: Potential Application in Early Detection and a Regulatory Role in Tumorigenesis Pathways , 2020, Cancers.

[12]  Filip Roudnicky,et al.  Functional Genomics for Cancer Drug Target Discovery. , 2020, Cancer cell.

[13]  A. Carrato,et al.  First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study , 2020, ESMO Open.

[14]  Yue Du,et al.  Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2019, Pharmacology & therapeutics.

[15]  W. Berdel,et al.  Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer , 2019, Cancers.

[16]  T. Bivona,et al.  Polytherapy and Targeted Cancer Drug Resistance. , 2019, Trends in cancer.

[17]  Zhongliang Ma,et al.  Biology of MiR-17-92 Cluster and Its Progress in Lung Cancer , 2018, International journal of medical sciences.

[18]  N. Munshi,et al.  Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. , 2018, Blood.

[19]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[20]  N. Munshi,et al.  Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity , 2018, Leukemia.

[21]  Y. Li,et al.  Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity , 2018, Cell Death & Disease.

[22]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[23]  Zhengxiang Shan,et al.  MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. , 2017, International journal of oncology.

[24]  W. Kim,et al.  Molecular Testing of Lung Cancers , 2017, Journal of pathology and translational medicine.

[25]  N. Waterhouse,et al.  Detecting Cleaved Caspase-3 in Apoptotic Cells by Flow Cytometry. , 2016, Cold Spring Harbor protocols.

[26]  W. Cui,et al.  Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination , 2016, Development.

[27]  A. Shaw,et al.  Resisting Resistance: Targeted Therapies in Lung Cancer. , 2016, Trends in cancer.

[28]  C. Zappa,et al.  Non-small cell lung cancer: current treatment and future advances. , 2016, Translational lung cancer research.

[29]  L. Amable.  Cisplatin resistance and opportunities for precision medicine. , 2016, Pharmacological research.

[30]  Vikas Gupta,et al.  MicroRNA therapeutics: Discovering novel targets and developing specific therapy , 2016, Perspectives in clinical research.

[31]  Yong Peng,et al.  The role of MicroRNAs in human cancer , 2016, Signal Transduction and Targeted Therapy.

[32]  Ronit Vogt Sionov,et al.  Regulation of Bim in Health and Disease , 2015, Oncotarget.

[33]  L. Galluzzi,et al.  Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.

[34]  S. Lam,et al.  Genetic alterations defining NSCLC subtypes and their therapeutic implications. , 2013, Lung cancer.

[35]  A. Berns,et al.  Mouse models for lung cancer , 2013, Molecular oncology.

[36]  Yi-rong Wang,et al.  miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. , 2012, Oncology reports.

[37]  F. Slack,et al.  MicroRNAs in mutagenesis, genomic instability, and DNA repair. , 2011, Seminars in oncology.

[38]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[39]  Lin He,et al.  mir-17-92, a cluster of miRNAs in the midst of the cancer network. , 2010, The international journal of biochemistry & cell biology.

[40]  P. Massion,et al.  High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications , 2009, European Respiratory Journal.

[41]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[42]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.